Lisbeth Nilvebrant

1.3k total citations
29 papers, 1.1k citations indexed

About

Lisbeth Nilvebrant is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Urology. According to data from OpenAlex, Lisbeth Nilvebrant has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 15 papers in Cellular and Molecular Neuroscience and 9 papers in Urology. Recurrent topics in Lisbeth Nilvebrant's work include Receptor Mechanisms and Signaling (20 papers), Neuropeptides and Animal Physiology (14 papers) and Ion channel regulation and function (9 papers). Lisbeth Nilvebrant is often cited by papers focused on Receptor Mechanisms and Signaling (20 papers), Neuropeptides and Animal Physiology (14 papers) and Ion channel regulation and function (9 papers). Lisbeth Nilvebrant collaborates with scholars based in Sweden, Canada and United Kingdom. Lisbeth Nilvebrant's co-authors include Bengt Sparf, Gregor Larsson, B. Hallén, Per‐Göran Gillberg, Matthias Stahl, K. Andersson, Anders Mattiasson, Karl‐Erik Andersson, Uli Hacksell and Gunnar Nordvall and has published in prestigious journals such as Journal of Medicinal Chemistry, The Journal of Urology and Life Sciences.

In The Last Decade

Lisbeth Nilvebrant

29 papers receiving 1.0k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Lisbeth Nilvebrant 595 362 329 290 248 29 1.1k
R. Testa 251 0.4× 285 0.8× 71 0.2× 104 0.4× 200 0.8× 49 908
Tomomi Oki 249 0.4× 208 0.6× 115 0.3× 96 0.3× 137 0.6× 34 639
Steven A. Buckner 335 0.6× 434 1.2× 59 0.2× 58 0.2× 154 0.6× 57 986
Michael E. Brune 182 0.3× 251 0.7× 38 0.1× 54 0.2× 83 0.3× 41 746
Rodolfo Testa 176 0.3× 280 0.8× 40 0.1× 35 0.1× 182 0.7× 34 617
Shuji Maruyama 157 0.3× 75 0.2× 90 0.3× 79 0.3× 40 0.2× 15 357
Michael K. James 73 0.1× 359 1.0× 10 0.0× 27 0.1× 335 1.4× 33 1.0k
Chafiq Moummi 30 0.1× 171 0.5× 28 0.1× 14 0.0× 161 0.6× 22 518
James S. Polakowski 35 0.1× 405 1.1× 11 0.0× 21 0.1× 147 0.6× 39 900
Cynthia J. Harris 38 0.1× 76 0.2× 32 0.1× 21 0.1× 38 0.2× 13 481

Countries citing papers authored by Lisbeth Nilvebrant

Since Specialization
Citations

This map shows the geographic impact of Lisbeth Nilvebrant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisbeth Nilvebrant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisbeth Nilvebrant more than expected).

Fields of papers citing papers by Lisbeth Nilvebrant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisbeth Nilvebrant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisbeth Nilvebrant. The network helps show where Lisbeth Nilvebrant may publish in the future.

Co-authorship network of co-authors of Lisbeth Nilvebrant

This figure shows the co-authorship network connecting the top 25 collaborators of Lisbeth Nilvebrant. A scholar is included among the top collaborators of Lisbeth Nilvebrant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisbeth Nilvebrant. Lisbeth Nilvebrant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Påhlman, Ingrid, et al.. (2011). Tissue Distribution of Tolterodine, a Muscarinic Receptor Antagonist, and Transfer into Fetus and Milk in Mice. Arzneimittelforschung. 51(2). 125–133. 8 indexed citations
2.
Nilvebrant, Lisbeth. (2002). Tolterodine and its Active 5‐Hydroxymethyl Metabolite: Pure Muscarinic Receptor Antagonists. Pharmacology & Toxicology. 90(5). 260–267. 15 indexed citations
3.
Chapple, Christopher R. & Lisbeth Nilvebrant. (2002). Tolterodine: Selectivity for the Urinary Bladder Over the Eye (as Measured by Visual Accommodation) in Healthy Volunteers. Drugs in R&D. 3(2). 75–81. 15 indexed citations
4.
Nilvebrant, Lisbeth. (2001). Clinical experiences with tolterodine. Life Sciences. 68(22-23). 2549–2556. 22 indexed citations
5.
6.
Larsson, Gregor, B. Hallén, & Lisbeth Nilvebrant. (1999). Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology. 53(5). 990–998. 82 indexed citations
7.
Gillberg, Per‐Göran, et al.. (1998). Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. European Journal of Pharmacology. 349(2-3). 285–292. 69 indexed citations
8.
Nilvebrant, Lisbeth, Per‐Göran Gillberg, & Bengt Sparf. (1997). Antimuscarinic Potency and Bladder Selectivity of PNU‐200577, a Major Metabolite of Tolterodine. Pharmacology & Toxicology. 81(4). 169–172. 84 indexed citations
9.
Nilvebrant, Lisbeth, B. Hallén, & Gregor Larsson. (1997). Tolterodine-a new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data. Life Sciences. 60(13-14). 1129–1136. 154 indexed citations
10.
Nilvebrant, Lisbeth, et al.. (1997). Tolterodine – a new bladder-selective antimuscarinic agent. European Journal of Pharmacology. 327(2-3). 195–207. 244 indexed citations
11.
Johansson, Gary, et al.. (1997). Antimuscarinic 3-(2-Furanyl)quinuclidin-2-ene Derivatives:  Synthesis and Structure−Activity Relationships. Journal of Medicinal Chemistry. 40(23). 3804–3819. 20 indexed citations
12.
Nordvall, Gunnar, et al.. (1996). Chapter 11 3-Heteroarylquinuclidin-2-ene derivatives as muscarinic antagonists: synthesis, structure-activity relationships and molecular modelling. Progress in brain research. 109. 141–145. 7 indexed citations
13.
Johansson, Gary, et al.. (1995). 3-Heteroaryl-Substituted Quinuclidin-3-ol and Quinuclidin-2-ene Derivatives as Muscarinic Antagonists. Synthesis and Structure-Activity Relationships. Journal of Medicinal Chemistry. 38(3). 473–487. 21 indexed citations
14.
Hacksell, Uli, et al.. (1995). Quinuclidin-2-ene - based muscarinic antagonists. Life Sciences. 56(11-12). 831–836. 1 indexed citations
15.
Nordvall, Gunnar, et al.. (1994). 3-Lithioquinuclidin-2-ene: A novel intermediate for the synthesis of muscarinic agonists and antagonists. Bioorganic & Medicinal Chemistry Letters. 4(24). 2837–2840. 7 indexed citations
16.
Nordvall, Gunnar, et al.. (1992). Analogs of the muscarinic agent 2'-methylspiro[1-azabicyclo[2.2.2]octane-3,4'-[1,3]dioxolane]: synthesis and pharmacology. Journal of Medicinal Chemistry. 35(9). 1541–1550. 8 indexed citations
17.
Nilvebrant, Lisbeth & Conny Nordin. (1991). Affinity of Nortriptyline and its E‐10‐Hydroxy Metabolite for Muscarinic Receptors. Pharmacology & Toxicology. 68(1). 64–67. 7 indexed citations
18.
Nilvebrant, Lisbeth & Bengt Sparf. (1988). Receptor binding profiles of some selective muscarinic antagonists. European Journal of Pharmacology. 151(1). 83–96. 30 indexed citations
19.
Nilvebrant, Lisbeth & Bengt Sparf. (1986). Dicyclomine, benzhexol and oxybutynine distinguish between subclasses of muscarinic binding sites. European Journal of Pharmacology. 123(1). 133–143. 68 indexed citations
20.
Nilvebrant, Lisbeth, Karl‐Erik Andersson, & Anders Mattiasson. (1985). Characterization of the Muscarinic Cholinoceptors in the Human Detrusor. The Journal of Urology. 134(2). 418–423. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Testa Breakdown of academic impact, for papers by Tomomi Oki Breakdown of academic impact, for papers by Steven A. Buckner Breakdown of academic impact, for papers by Michael E. Brune Breakdown of academic impact, for papers by Rodolfo Testa Breakdown of academic impact, for papers by Shuji Maruyama Breakdown of academic impact, for papers by Michael K. James Breakdown of academic impact, for papers by Chafiq Moummi Breakdown of academic impact, for papers by James S. Polakowski Breakdown of academic impact, for papers by Cynthia J. Harris
Rankless by CCL
2026